

To our shareholders

Securities Code 4483  
June 5, 2026

2-5-5 Shiba Daimon, Minato-ku, Tokyo  
President and CEO  
JMDC Inc.  
Ryo Noguchi

### Notice of the 13th Annual General Meeting of Shareholders

We would like to take this opportunity to express our sincere gratitude for your continued support.

We are pleased to inform you that the 13th Annual General Meeting of Shareholders of JMDC Inc. (the "Company") will be held as follows.

When convening this General Meeting of Shareholders, the Company has taken measures for electronic provision of the information contained in the reference documents for the General Meeting of Shareholders, etc. (matters regarding measures for electronic provision), and has posted the information on the Company's website on the Internet. Please access the following website to view the information.

◎ Company website: <https://www.jmdc.co.jp/>



(Please access the above website and select "IR News," "Stock-related Information" and "General Meeting of Shareholders" from the menu.)

In addition, matters regarding measures for electronic provision are posted on the website of the Tokyo Stock Exchange (TSE) in addition to the Company's website. Please access the website below:

◎ Tokyo Stock Exchange Website (Listed Company Search)  
<https://www2.jpx.co.jp/tseHpFront/JJK010010Action.do?Show=Show>



(Please access the TSE website above, enter "JMDC" in "Issue name (company name)" or the Company's Securities Code "4483" in "Code" to search, select "Basic Information" and then "Documents for public inspection/PR information," and read the "Notice of General Shareholders Meeting/Informational Materials for a General Shareholders Meeting" section in the "Documents for public inspection.")

In lieu of attending the meeting in person, you may exercise your voting rights via the Internet or in writing (by mail). Please review the reference documents for the General Meeting of Shareholders and exercise your voting rights by no later than 6:00 p.m. on Wednesday, June 24, 2026 (JST).

Sincerely

1. Date and Time Thursday, June 25, 2026, 10:00 a.m. (JST)
2. Venue 2-3-1 Hamamatsucho, Minato-ku, Tokyo  
Hamamatsucho Convention Hall, Nippon Life Hamamatsucho Crea Tower 5F
3. Agenda
  - Matters to be Reported
    1. Business report and report on the Consolidated Financial Statements for the 13th Fiscal Year (from April 1, 2025 to March 31, 2026), and report on the results of audit of the Consolidated Financial Statements by the Accounting Auditor and the Audit & Supervisory Board
    2. Report on the Non-Consolidated Financial Statements for the 13th Fiscal Year (April 1, 2025 to March 31, 2026)
  - Matters to be Resolved
    - Proposal 1 Election of Five (5) Directors (excluding Directors who are Audit & Supervisory Board Members)
    - Proposal 2 Election of One (1) Director who is an Audit & Supervisory Board Member

No souvenirs will be provided for shareholders attending the General Meeting of Shareholders. We appreciate your understanding.

#### Matters Determined for Convocation (Guide to Exercising Voting Rights)

- ⊙ You may exercise your voting rights by proxy only in the case where the proxy who is another shareholder with voting rights attends the General Meeting of Shareholders. However, please note that the proxy will be required to present written proof of his/her right of proxy.
- ⊙ Should the matters regarding measures for electronic provision require revisions, the information before the revision and the information after the revision will be posted on the Company's website on the Internet and the TSE website.
- ⊙ In accordance with laws and regulations and the provisions of our Articles of Incorporation, the following matters regarding measures for electronic provision are not provided on the documents delivered to the shareholders requesting for delivery of documents. The Audit & Supervisory Board and our Accounting Auditor have performed the audit on the documents to be audited, including the following items:
  - 1) "Consolidated statement of changes in equity" and "Tables of explanatory notes on consolidated financial statements" included in the report on the Consolidated Financial Statements, and
  - 2) "Statement of changes in shareholders' equity" and "Tables of explanatory notes on unconsolidated financial statements" included in the report on the financial statements.

#### Notice of Post-Event Streaming

The video recording of a part of the General Meeting of Shareholders will be made available for post-event streaming on our website below. In the event that the streaming is canceled due to unavoidable circumstances, a notice will be posted on our website.

- ⊙ <https://www.jmdc.co.jp/ir/meeting/>



Reference Documents for the General Meeting of Shareholders

Proposal 1 Election of Five (5) Directors (excluding Directors who are Audit & Supervisory Board Members)

The terms of office of all (5) Directors (excluding Directors who are Audit & Supervisory Board Members. The same shall apply hereinafter in this proposal.) will expire at the conclusion of this General Meeting of Shareholders. Therefore, the Company proposes to elect five (5) Directors.

The Board of Directors determines the candidates for the Board of Directors based on the report of the Nomination and Compensation Committee, a voluntary advisory body to the Board of Directors. In addition, the Company's Audit & Supervisory Board has determined that all candidates for the Board of Directors are suitable for the position.

The candidates for the Board of Directors are as follows.

Candidate No.	Name (Date of birth)	Career summary, position and responsibility in the Company (Significant concurrent positions)	Number of Company shares held
1	Yosuke Matsushima (September 1, 1972) <div style="border: 1px solid black; padding: 2px; display: inline-block;">Reappointment</div>	April 1995    Joined The Dai-ichi Life Insurance Company, Limited June 2001    Joined A.T. Kearney October 2005    Joined McKinsey & Company, Inc. February 2007    Joined MKS Partners Limited. December 2008    Joined Marunouchi Capital Inc. April 2012    Representative Director of NK Relations Co. Ltd. (currently Noritsu Koki Co., Ltd.) July 2012    Director of NS Partners Co. Ltd May 2013    Director of the Company June 2013    Executive Vice President and COO of Noritsu Koki Co., Ltd. October 2013    President and Representative Director of the Company October 2014    Resigned as Representative Director of the Company (Part-time Director) July 2015    Director of Doctor Net Inc. June 2016    Outside Director of PKSHA Technology Inc. April 2018    President and CEO, Representative Director of the Company June 2018    Director of Medical Database Co., Ltd. April 2020    Director of NS Partners Co. Ltd November 2020    Director of Data Index Corporation June 2023    Chairman and Representative Director of the Company October 2023    Outside Director of KARADANOTE INC. (to present) June 2023    Chairman and Director of the Company (to present)	565,178 shares
[Reasons for nomination] Since his appointment as a Director of the Company, Yosuke Matsushima has been responsible for the management of our whole group as President and Representative Director and as Chairperson and Representative Director, and has driven the enhancement of corporate value. With his extensive experience, track record, and insight in corporate management, we believe that he is an appropriate candidate for the realization of the Group's strategies and the further growth of the Group in the future as well, and we continue to nominate him as a candidate for Director.			

Candidate No.	Name (Date of birth)	Career summary, position and responsibility in the Company (Significant concurrent positions)	Number of Company shares held
2	Ryo Noguchi (August 27, 1980) Reappointment	<p>April 2007    Joined Boston Consulting Group</p> <p>September 2016    Joined NK Relations Co. Ltd. (currently Noritsu Koki Co., Ltd.)</p> <p>October 2016    Representative Director of GeneTech Co., Ltd.</p> <p>June 2017    Representative Director of Japan Regenerative Medicine Co., Ltd. (currently Metcela Inc.)</p> <p>June 2018    Director of Gene Techno Science Co., Ltd. (currently Kidswell Bio Corporation)</p> <p>May 2020    Executive Officer of the Company (in charge of Pharmaceutical Division)</p> <p>April 2022    Executive Officer of the Company (in charge of Insurer Support Business Division)</p> <p>December 2022    Executive Officer of the Company (in charge of the Pharmaceutical Division and the Medical Institution Support Business Division)</p> <p>June 2023    President and CEO, Representative Director of the Company (to present)</p> <p>June 2023    Director of Doctor Net Inc. (to present)</p> <p>June 2023    Director of NS Partners Co. Ltd (to present)</p> <p>January 2024    Director of Cancerscan Inc. (to present)</p>	72,596 shares
<p>[Reasons for nomination]</p> <p>Ryo Noguchi has excellent management judgment skills based on his practical experience in the medical and healthcare industries and has served as President and Representative Director of the Company since June 2023 having held important positions in each department of pharmaceuticals, insurer support, and medical institution support, which are our main businesses. With his wealth of insight into the overall business of the Company's group, we believe that his track record, knowledge, and expertise are appropriate for achieving the further growth of the Company's group in the future as well, and we continue to nominate him as a candidate for Director.</p>			

Candidate No.	Name (Date of birth)	Career summary, position and responsibility in the Company (Significant concurrent positions)	Number of Company shares held
3	Yuta Yamamoto (December 14, 1982)  Reappointment	<p>April 2007    Joined Boston Consulting Group</p> <p>May 2012    Joined NK Relations Co. Ltd. (currently Noritsu Koki Co., Ltd.)</p> <p>May 2013    Director of the Company</p> <p>January 2014    Registered as an attorney-at-law</p> <p>                  Established Yuta Yamamoto Law Office, Representative (currently Yamamoto Law Office) (to present)</p> <p>June 2015    Director of Noritsu Koki Co., Ltd.</p> <p>June 2016    Director of Doctor Net Inc.</p> <p>April 2019    Executive Officer, Vice President, and CFO of the Company</p> <p>June 2019    Director of Medical Database Co., Ltd.</p> <p>June 2019    Director of Doctor Net Inc.</p> <p>April 2020    Director of NS Partners Co. Ltd</p> <p>June 2020    Vice President and CFO, Director of the Company</p> <p>August 2020    Outside Director of Outside Director of AViC Co., Ltd.</p> <p>November 2020    Director of Data Index Corporation</p> <p>December 2021    Director (Audit &amp; Supervisory Committee Member) of AViC Co., Ltd. (to present)</p> <p>June 2023    Director of the Company (to present)</p>	498,950 shares
<p>[Reasons for nomination]</p> <p>Yuta Yamamoto has excellent business judgment skills based on his past business experience, and as CFO of the Company, he has served in an important role in the department responsible for the accounting and financial strategies of the Company's group. With his wealth of insight into the overall business of the Company's group, we believe that his track record, knowledge, and expertise are appropriate for achieving the further growth of the Company's group in the future as well, and we continue to nominate him as a candidate for Director.</p>			

Candidate No.	Name (Date of birth)	Career summary, position and responsibility in the Company (Significant concurrent positions)	Number of Company shares held
4	Seiji Takeda (June 12, 1967) <b>Reappointment</b>	<p>April 1990    Joined OMRON Corporation</p> <p>July 2006    Deputy General Manager of Omron Healthcare (China) Co., Ltd.</p> <p>October 2011    Vice President of Omron Healthcare, Inc. and President of Omron Healthcare Brasil Indústria e Comércio de Produtos Médicos Ltda.</p> <p>April 2013    General Manager, Global Sales Planning Division and General Manager, U.S. and European Sales Headquarters of OMRON HEALTHCARE Co., Ltd. and CEO of Omron Healthcare, Inc.</p> <p>March 2017    General Manager, Corporate Strategy Department, Global Strategy Division of OMRON Corporation</p> <p>April 2018    Executive Officer of OMRON Corporation</p> <p>June 2022    Outside Director of the Company</p> <p>April 2023    Managing Executive Officer, CFO and General Manager of Global Strategy Division of OMRON Corporation</p> <p>October 2023    Director of the Company (to present)</p> <p>April 2024    Senior Managing Executive Officer, CFO and General Manager of Global Strategy Division of OMRON Corporation (to present)</p> <p>(Significant concurrent positions) Senior Managing Executive Officer, CFO and General Manager of Global Strategy Division of OMRON Corporation</p>	-
<p>[Reasons for nomination]</p> <p>Seiji Takeda has experience as Officer of OMRON Corporation and as Manager in Japan and overseas, and has broad insight in the healthcare area. We believe that he will use such insights and experience to contribute to the Company, especially to promoting our global development and is an appropriate person for achieving further growth of the Group in the future. Therefore, we continue to nominate him as a candidate for Director.</p>			

Candidate No.	Name (Date of birth)	Career summary, position and responsibility in the Company (Significant concurrent positions)	Number of Company shares held
5	Jihyun Lee (February 28, 1967) Reappointment	December 1988 Joined Durban Korea Co. April 1997 Joined Boston Consulting Group April 2000 Joined transcosmos inc. April 2001 Director of transcosmos inc. April 2001 Supervisory Vice President COO of CIC Korea Inc. (currently transcosmos Korea inc.) April 2003 Advisor of transcosmos inc. August 2004 Joined Russell Reynolds Associates Japan Inc. February 2007 Representative Director of Raise Partners, Inc (to present) July 2007 Visiting professor of the Graduate School of Management, GLOBIS University June 2021 Outside Director of the Company (to present) June 2023 Outside Director of Striders Corporation June 2023 Director who is an Audit & Supervisory Board Member of Striders Corporation (to present) (Significant concurrent positions) Representative Director of Raise Partners, Inc	-
[Reasons for nomination and summary of expected roles] Jihyun Lee has experience as Executive of a listed company and as Manager in Japan and overseas. She also has broad insight into fostering leaders based on her experience as a human resources consultant, as a teacher, and as an Outside Director of the Company. We continue to nominate her as a candidate for Outside Director as we expect her in particular to contribute to the promotion of diversity by utilizing her knowledge and experience, and to provide objective opinions and suggestions on management policies and strategies to enhance the corporate value of the Company's group.			

- (Note) 1. OMRON Corporation is our parent company. The current and past ten years' positions and responsibilities at the said parent company, etc., of Seiji Takeda, a candidate for Director, are as described in the "Career summary, position and responsibility in the Company (Significant concurrent positions)" section above.
2. Seiji Takeda, a candidate for Director, is an Executive Officer of OMRON Corporation, our parent company. We have concluded a capital and business alliance agreement with the company and purchase products from it and provide and outsource services related to medical data, etc. to the company. There are no special interests between other candidates and the Company.
3. Jihyun Lee is a candidate for Outside Director.
4. Jihyun Lee is currently an Outside Director of the Company. The term of office as Outside Director will be five (5) years at the conclusion of this General Meeting of Shareholders.
5. Pursuant to Article 427, Paragraph 1 of the Companies Act, the Company has entered into an agreement with Seiji Takeda and Jihyun Lee to limit their liability for damages under Article 423, Paragraph 1 of the said Act. The maximum amount of liability for damages under the said agreement is the amount stipulated in laws and regulations, and if the reappointment of Seiji Takeda and Jihyun Lee is approved, the Company plans to continue the said agreement with each of them.
6. The Company is included as a named subsidiary under the Directors and Officers (D&O) liability insurance policy that our parent company, OMRON Corporation, has concluded with an insurance company, and an outline of the content of said insurance policy is as described in 2. (3) (4) "Outline of Directors and Officers Liability Insurance Contract" in the Business Report. (It is only available in the Japanese version.) If each of the candidates is elected as a Director and assumes office, each of them will be an insured person under the said insurance policy.
7. The Company has registered Jihyun Lee as Independent Director as stipulated by the Tokyo Stock Exchange. If his reappointment is approved, the Company plans to continue to nominate him as Independent Director.

Proposal 2 Election of One (1) Director who is an Audit & Supervisory Board Member

One (1) of the four (4) Directors who are Audit & Supervisory Board Members will expire at the conclusion of this General Meeting of Shareholders. Therefore, the Company proposes to elect one (1) Director who is an Audit & Supervisory Board Member.

The Company has obtained the consent of the Audit & Supervisory Board with regard to the submission of this proposal.

The candidate for Director who is an Audit & Supervisory Board Member is as follows:

Name (Date of birth)	Career summary, position and responsibility in the Company (Significant concurrent positions)	Number of Company shares held
<p>Nanako Tamiya (July 7, 1960)</p> <div style="border: 1px solid black; padding: 2px; width: fit-content; margin: 5px auto;">New appointment</div>	<p>July 1991 Assistant Professor of the Institute of Community Medicine, University of Tsukuba</p> <p>September 1992 Assistant Professor of the Department of Hygiene and Public Health, Teikyo University School of Medicine</p> <p>April 1999 Director of the Minami-Yamato Geriatric Health Services Facility</p> <p>June 2000 Senior Lecturer of the Department of Hygiene and Public Health, Teikyo University School of Medicine</p> <p>April 2003 Professor of the Institute of Community Medicine, University of Tsukuba</p> <p>April 2004 Professor of the Health Services Research, Graduate School of Comprehensive Human Sciences, University of Tsukuba (Currently Faculty of Medicine, University of Tsukuba)</p> <p>July 2017 Director of the Health Services Research and Development Center, University of Tsukuba (to present)</p> <p>April 2026 Specially Appointed Professor (Health Services Research) of the Faculty of Medicine, University of Tsukuba (to present)</p> <p>(Significant concurrent positions) Director of the Health Services Research and Development Center, University of Tsukuba Specially Appointed Professor (Health Services Research) of the Faculty of Medicine, University of Tsukuba</p>	-
<p>[Reasons for nomination and summary of expected roles]</p> <p>Nanako Tamiya possesses extensive expertise and insight gained from her tenure as a professor in the field of Health Services Research at the Faculty of Medicine, University of Tsukuba. With such experience and insights, we expect her to provide objective opinions and appropriate advice on the Company's management from a neutral standpoint, and we believe that she is an appropriate person for auditing the Company's business operation. If she is appointed, we expect her to provide appropriate advice on our management strategies and business operation and perform fair audits as an Outside Director who is an Audit &amp; Supervisory Board Member.</p>		

- (Note) 1. There are no special interests between each candidate and the Company.
2. Nanako Tamiya is a candidate for Outside Director who is an Audit & Supervisory Board Member. Furthermore, she meets the requirements for an independent officer as stipulated by the Tokyo Stock Exchange. If her election is approved, the Company plans to register her as an independent officer with the said Exchange.
3. If the election of Nanako Tamiya is approved, the Company plans to enter into an agreement with her to limit her liability for damages under Article 423, Paragraph 1 of the Companies Act, pursuant to the provisions of Article 427, Paragraph 1 of the said Act. The maximum amount of liability for damages under the said agreement shall be the amount stipulated by laws and regulations.
4. The Company is included as a named subsidiary under the Directors and Officers (D&O) liability insurance policy that our parent company, OMRON Corporation, has concluded with an insurance company, and an outline of the content of said insurance policy is as described in 2. (3) (4) "Outline of Directors and Officers Liability Insurance Contract" in the Business Report. (It is only available in the Japanese version.) If Nanako Tamiya is elected as a Director who is an Audit & Supervisory Board Member and assumes office, she will be an insured person under the said insurance policy.

In addition to "corporate management," which is the basic skill of corporate management, the Company has established industry experience and knowledge, M&A and business development, IT and technology, legal and compliance, dialog with capital markets and financial accounting, global business, and ESG/SDGs as the necessary skill sets regarding expert knowledge and experience which Directors are required to have. If both Proposal 1 and Proposal 2 are approved, the skill matrix of Directors and Directors who are Audit & Supervisory Board Members will be as follows:

Name	Attributes	Corporate management	Industry experience and Knowledge	M&A and Business development	IT and Technology	Legal and Compliance	Dialog with capital markets and Financial accounting	Global business	ESG and SDGs
Directors									
Yosuke Matsushima		○	○	○	○		○	○	
Ryo Noguchi		○	○			○	○	○	○
Yuta Yamamoto		○		○	○	○	○		
Seiji Takeda		○	○	○			○	○	
Jihyun Lee	[Outside] [Independent]	○		○				○	○
Directors who are Audit & Supervisory Board Members									
Tsuneo Shimoda	[Outside] [Independent]	○	○			○	○		
Nampe Hayashi	[Outside] [Independent]	○		○	○		○		
Daisuke Fujioka	[Outside] [Independent]	○			○	○	○		
Nanako Tamiya	[New appointment] [Outside] [Independent]	○	○			○			○

[New appointment] Newly appointed candidates [Outside] Candidates for Outside Directors [Independent] Candidates for Independent Directors